Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Study Identifies Proteins That Allow Blood Vessels to Grow

Blood vessels run throughout the human body and ensure that our organs get all the nutrients and oxygen they need. An international research group has now discovered how two proteins named YAP and TAZ play a crucial role in allowing new blood vessels to sprout

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Blood vessels run throughout the human body and ensure that our organs get all the nutrients and oxygen they need. An international research group has now discovered how two proteins named YAP and TAZ play a crucial role in allowing new blood vessels to sprout, even under challenging metabolic conditions. The proteins are part of the Hippo signaling pathway, which regulates organ growth and size in almost all living things.

Michael Potente, PhD, and Holger Gerhardt, PhD, and their research teams now want to study how much the mechanism—which they described during tissue development—is also involved in regeneration and repair processes that rely heavily on blood vessels. “We’re primarily interested in finding out whether and, if relevant, how malfunctions in that signaling pathway can cause vascular diseases in humans,” said Potente, who is a professor for translational vascular biomedicine at the Berlin Institute of Health at Charité (BIH) and a guest researcher at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC). Gerhardt is head of the Integrative Vascular Biology Laboratory at the MDC, and works next door to Potente in the Käthe Beutler Building in Berlin-Buch.

The researchers reported on their work in Nature Metabolism, in a paper titled, “A YAP/TAZ-TEAD signaling module links endothelial nutrient acquisition to angiogenic growth.”

Blood vessels form extensive tubular networks of arteries, capillaries, and veins that nurture all body tissues, the authors wrote. If these finely woven networks stop working as they should, we risk developing diseases.

While age-related cardiovascular conditions frequently cause blood vessels to atrophy, malignant tumors are characterized by excessive growth of misrouted vessels. Wet macular degeneration is also associated with the sprouting of new blood vessels in the wrong place. At its worst, this condition can cause blindness.

Endothelial cells (ECs) line the inner surface of blood vessels, where they are surrounded by diverse nutrients such as amino acids, glucose, and lipids.” Angiogenesis, the process by which endothelial cells form new blood vessels from existing ones, requires increased nutrient uptake and consumption by these cells to meet the increased metabolic demands. The authors further pointed out, “Controlling nutrient acquisition and usage is, therefore, central to the function of the endothelium; yet, the mechanisms that regulate these processes are poorly understood … how endothelial nutrient acquisition and usage are regulated is unknown.”

Potente said, “To help us develop targeted therapies for these kinds of disease, we want to find out how exactly the growth of new blood vessels—a process called angiogenesis—is regulated within the body. His angiogenesis & metabolism laboratory is part of the Berlin Center for Translational Vascular Biomedicine, an interdisciplinary facility that is a joint focus area of the BIH, Charité—Universitätsmedizin Berlin, and the MDC.

The findings are based on mouse experiments. The mouse retina is an ideal model for studying blood vessel development. “YAP and TAZ are effectors of the Hippo pathway and essential regulators of vascular development, whose activity is highly sensitive to changes in the micro-environment,” the authors said. “By sensing and responding to mechanical, metabolic, and soluble signals, these proteins coordinate tissue growth responses.”

“Using genetically modified mouse lines, we showed how endothelial cells that don’t produce YAP and TAZ almost never divide,” said Potente. “This inhibited vessel growth in the mice.” The TAZ protein plays an especially important role in this process, while YAP is the decisive factor in most other types of cells. Compared to YAP, TAZ was also the more abundant transcript in various endothelial subtypes suggesting a critical role of TAZ for YAP/TAZ responses in the endothelium,” the team noted. They further explained, “ECs lacking YAP/TAZ or their transcriptional partners, TEAD1, 2, and 4 fail to divide, resulting in stunted vascular growth in mice. Conversely, activation of TAZ, the more abundant paralogue in ECs, boosts proliferation, leading to vascular hyperplasia.”

The new findings have shown that if YAP and TAZ are active in the cells of the endothelium, they effectively read genes that lead to increased growth of certain surface transporters, Potente said. “These allow the vessel cells to absorb more nutrients that are important for growth and cell division.” YAP and TAZ, which both function in a similar way, therefore act as a kind of door-opener.

“Because new blood vessels frequently form in tissues with a poor blood supply, endothelial cells must be able to grow in the most challenging metabolic conditions,” said Potente. “That’s why it’s so important for these cells to have molecular machinery that recognizes and reacts to subtle changes in the extracellular milieu.”

He further explained, “This increased absorption of nutrients leads to the activation of another protein, called mTOR.” mTOR is an important control point in the cells that trigger growth and cell division. “This allows new blood vessel networks to expand.”

The team does not yet know which signals regulate the activity of YAP and TAZ in endothelial cells. Nevertheless, Gerhardt noted, “Together, we’ve discovered a mechanism that enables blood vessels to align their growth closely to the situation in their surroundings. The mechanism stops endothelial cells from dividing if the metabolic resources needed for the process aren’t there.”

The authors concluded, “Our study identifies an essential metabolic link between YAP/TAZ and angiogenic growth, which involves the master regulator of cellular anabolism, TORC1 … Delineating the mechanisms that determine how ECs take up, transport, and use nutrients will provide new insights not only into vascular (patho-)physiology but also into the role of specific nutrients in instructing vascular growth and function.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
02How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →